📇 Rhumatologue · PARIS CEDEX 14 · (75) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
79
79 articles ont été cités au moins 79fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
29 706
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
594
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
253
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Paris Saint-Joseph
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
2026ArticleJNCI: Journal of the National Cancer Institute
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
2025ArticleThe Lancet
The International Work Addiction Scale (IWAS): A screening tool for clinical and organizational applications validated in 85 cultures from six continents
2025ArticleJournal of Behavioral Addictions
Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors
2023ArticleCells
Self-construals predict personal life satisfaction with different strengths across societal contexts differing in national wealth and religious heritage
2023ArticleSelf and Identity
Unpackaging the link between economic inequality and self-construal
2023ArticleSelf and Identity
Management of unexpected laboratory exposure to Burkholderia pseudomallei
2023ArticleAnnales de Biologie Clinique
Introduction to a Culturally Sensitive Measure of Well-Being: Combining Life Satisfaction and Interdependent Happiness Across 49 Different Cultures
2022ArticleJournal of Happiness Studies
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GH PARIS SITE SAINT JOSEPH
185 R RAYMOND LOSSERAND, 75674 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Oncology · 2023
Oncoimmunology · 2017
International journal of cancer · 2018
The selective MEK1/2 inhibitor pimasertib has shown anti‐tumour activity in a pancreatic tumour model. This phase I/II, two‐part trial was conducted in patients with metastatic pancreatic adenocarcinoma (mPaCa) (NCT01016483). In the phase I part, oral pimasertib was given once daily discontinuously (5 days on/2 days off treatment) or twice daily continuously (n = 53) combined with weekly gemcitabine (1,000 mg/m2) in 28‐day cycles to identify the recommended phase II dose (RP2D) of pimasertib. In the phase II part, patients were randomised to pimasertib (RP2D) or placebo plus weekly gemcitabine (n = 88) to investigate progression‐free survival (PFS), overall survival (OS) and safety. The RP2D was determined to be 60 mg BID. PFS and OS outcomes did not indicate any treatment benefit for pimasertib over placebo in combination with gemcitabine (median PFS 3.7 and 2.8 months, respectively, HR = 0.91, 95% CI: 0.58–1.42: median OS 7.3 vs. 7.6 months, respectively). KRAS status did not influence PFS or OS. The incidence of grade ≥3 adverse events was 91.1% and 85.7% for pimasertib/gemcitabine and placebo/gemcitabine respectively, but there was a higher incidence of ocular events with pimasertib/gemcitabine (28.9% vs. 4.8% for placebo/gemcitabine). In conclusion, no clinical benefit was observed with first‐line pimasertib plus gemcitabine compared with gemcitabine alone in patients with mPaCa.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of insurance medicine (New York, N.Y.) · 2025 · Journal Article
Moll A, Raymond E, Schneider T, Vuillaume A, et al.
Therapeutic advances in medical oncology · 2024 · Journal Article
Lazar V, Raymond E, Magidi S, Bresson C, et al.
Therapeutic advances in medical oncology · 2023 · Journal Article
Lazar V, Zhang B, Magidi S, Le Tourneau C, et al.
Biomedicines · 2023 · Journal Article
Iseas S, Prost D, Bouchereau S, Golubicki M, et al.
Liver cancer · 2022 · Journal Article
Harding JJ, Awada A, Roth G, Decaens T, et al.
British journal of cancer · 2021 · Published Erratum
Decaens T, Barone C, Assenat E, Wermke M, et al.
Cureus · 2021 · Case Reports
Belaidi L, Baba-Hamed N, Savinelli F, Raymond E
British journal of cancer · 2021 · Clinical Trial, Phase I
Decaens T, Barone C, Assenat E, Wermke M, et al.
Targeted oncology · 2021 · Clinical Trial, Phase I
Lebbé C, Italiano A, Houédé N, Awada A, et al.
Targeted oncology · 2021 · Clinical Trial, Phase I
Delord JP, Italiano A, Awada A, Aftimos P, et al.
Investigational new drugs · 2019 · Journal Article
Brun S, Bassissi F, Serdjebi C, Novello M, et al.
International journal of cancer · 2018 · Clinical Trial, Phase I
Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, et al.
Oncoimmunology · 2017 · Journal Article
de Gramont A, Faivre S, Raymond E
Acta oncologica (Stockholm, Sweden) · 2016 · Journal Article
Sebbagh S, Roux J, Dreyer C, Neuzillet C, et al.
Liver international : official journal of the International Association for the Study of the Liver · 2025 · Journal Article
Gros L, Bouattour M, Dumont C, Dahan L, et al.
Therapeutic advances in medical oncology · 2024 · Journal Article
Hammel P, Smith D, Afchain P, Dominguez-Tinajero S, et al.
BMC cancer · 2023 · Clinical Trial, Phase II
Targeted oncology · 2021 · Journal Article
Fazio N, Kulke M, Rosbrook B, Fernandez K, et al.
Future oncology (London, England) · 2019 · Clinical Trial, Phase III
Valle JW, Borbath I, Rosbrook B, Fernandez K, et al.
Neuroendocrinology · 2018 · Journal Article
Raymond E, Kulke MH, Qin S, Yu X, et al.
Journal of the National Cancer Institute · 2026 · Journal Article
Joly F, Anota A, Chabaud S, Cropet C, et al.
Targeted oncology · 2016 · Clinical Trial, Phase III
Vinik A, Bottomley A, Korytowsky B, Bang YJ, et al.
Cells · 2023 · Journal Article
Bestion E, Raymond E, Mezouar S, Halfon P
Oral oncology · 2017 · Journal Article
Szturz P, Budíková M, Vermorken JB, Horová I, et al.
Neuroendocrinology · 2018 · Clinical Trial, Phase II
Pellat A, Dreyer C, Couffignal C, Walter T, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · Journal Article
Martin S, Fritsch A, Jouannaud C, Martin-Babau J, et al.
Journal of insurance medicine (New York, N.Y.) · 2023 · Journal Article
Plisson M, Moll A, Sarrazin V, Charles D, et al.
Oral oncology · 2017 · Journal Article
Szturz P, Budíková M, Vermorken JB, Horová I, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · Journal Article
Martin S, Fritsch A, Jouannaud C, Martin-Babau J, et al.
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features
With the goal of studying epigenetic alterations in fibrolamellar hepatocellular carcinoma (FLC) and establish an associated DNA methylation signature, we analyzed <i>LINE-1</i> methylation in a cohort of FLC and perform
Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects
Abstract Background Diffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas accounting for approximately a third of non-Hodgkin lymphomas. Prohibitin 1 (PHB1) and prohibitin 2 (PHB2) are scaffold proteins that p
Sunitinib In Patients With Pancreatic Neuroendocrine Tumors: Update of Safety Data
<b>Aim:</b> To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors. <b>Patients & methods:</b> Sunitinib- and placebo-tre
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features
With the goal of studying epigenetic alterations in fibrolamellar hepatocellular carcinoma (FLC) and establish an associated DNA methylation signature, we analyzed <i>LINE-1</i> methylation in a cohort of FLC and perform
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features
With the goal of studying epigenetic alterations in fibrolamellar hepatocellular carcinoma (FLC) and establish an associated DNA methylation signature, we analyzed <i>LINE-1</i> methylation in a cohort of FLC and perform
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features
With the goal of studying epigenetic alterations in fibrolamellar hepatocellular carcinoma (FLC) and establish an associated DNA methylation signature, we analyzed <i>LINE-1</i> methylation in a cohort of FLC and perform
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, et al.
The Lancet. Oncology · 2023 · Randomized Controlled Trial
Xu J, Kato K, Raymond E, Hubner RA, et al.
Targeted oncology · 2016 · Clinical Trial, Phase III
Vinik A, Bottomley A, Korytowsky B, Bang YJ, et al.
International journal of nanomedicine · 2016 · Clinical Trial, Phase I
Coriat R, Faivre SJ, Mir O, Dreyer C, et al.